The 13th Conference on
Protein Expression in Animal Cells (13th PEACe)
will be held from September 24-28, 2017
in Valencia, Spain
The goal of the 13th PEACe Conference is to continue the tradition of bringing together scientists from academia and industry to share knowledge in the field of recombinant protein expression.
Professor Nicole Borth,University of Natural Resources and Life Sciences (BOKU) and Austrian Centre of Industrial Biotechnology
Nicole is a world renown expert in the area of Chinese hamster ovary (CHO) cell omics, particularly being involved in the CHO genome project and pioneering work in the microRNA field in CHO cells. She ha slash developed analytical and sorting methods for identification of desirable properties in CHO cells for production of biotherapeutic proteins. Nicole will present on her latest work in the area of CHO cell omics at the meeting.
Dr Scott Estes Head of Upstream Process Development & Manufacturing, Codiak Biosciences
Scott will speak on the exciting potential of exosomes, covering the history and biology of exosomes alongside a description of how Codiak is approaching moving exosomes from the world of academic curiosity to a bonafide therapeutic platform.
PARTIAL LIST OF INVITED SPEAKERS
Nicole Borth, University of Natural Resources and Life Sciences (BOKU), Austria
Scott Estes, Codiak Biosciences, USA
Nicola Burgess-Brown, University of Oxford, UK
Nico Callewaert, VIB, Belgium
Leda Castilho, COPPE – Universidade Federal do Rio de Janeiro, Brazil
Yves Durocher, National research Council, Canada
Karl E. Griswold, Dartmouth University, USA
David James, University of Sheffield, UK
Nathan Lewis, University of California, San Diego, USA
Massimo Morbidelli, ETH Zurich, Switzerland
Umesh S. Muchhal, Xencor inc., USA
Gary Pettman, Medimmune, UK
Claudio Sustmann, F. Hoffmann-La Roche, Germany
Silvia Zucchelli, Scuola Internazionale Superiore di Studi Avanzati, Italy
Yuansheng Yang, BTI, Singapore
♣ Cell Engineering
Co-Chairs Kim Stutzman-Engwall, Consultant, USA - Linda Lua, University of Queensland, Australia
The production of complex biopharmaceutical proteins primarily uses mammalian cell expression systems due to the ability of these systems to produce and secrete correctly folded, functionally active recombinant proteins. Advances in synthetic biology tools for cell engineering have expedited cell line development for the production of high-quality biologics. This session will focus on new or novel methods and emerging technologies to modify or select cells to develop and establish recombinant cell lines. Topics of interest may include vector design and clone/host selection, codon optimization, genome engineering and editing tools, recombination mediated integration, and cell redesign.
♣ Protein Engineering
Co-Chairs Kim Stutzman-Engwall, Consultant, USA – René Hubert, Amgen, USA
Recombinant proteins in which protein structure or function are modified can vary widely in their biophysical characteristics. Typically, protein engineering applications include both rational protein design and directed evolution to generate proteins with desired functions. This session will focus on optimizing processes for improving quality and quantity of expressed proteins. Topics of interest may include selection and screening technologies, co-expression systems, antibody engineering, enhancing recombinant protein secretion, optimizing solubility, microRNA technologies, and CAR-T design.
♣ Expression systems
Co-Chairs Alan Dickson, University of Manchester, UK - Jesus Zurdo, Lonza , UK
CHO cells are at the top of the expression toolbox – for generation of products by transient or stable processes – and “standard” CHO cell variants are being expanded to include engineered varieties that impart specific functional properties to products. In this session, we will examine how the repertoire of expression platforms is extending beyond standard CHO cell lines (especially via the use of new synthetic biology approaches and more powerful gene editing technologies), tailoring host capabilities to match specific process and product requirement for the manufacture of existing and novel format products. Relevant topics will include CHO variants, other mammalian cell lines, non-mammalian cell systems engineered to replicate or extend CHO desirability (yeast, microbes, microalgae, plants), cell-free and synthetic platforms.
♣ Enhancing Expression and Quality of Difficult-to-Express Proteins
Co-Chairs Georg Schmid, Formerly at F. Hoffmann-La Roche, Switzerland – Bernie Sweeney (UCB – UK)
On top of “standard” monospecific antibodies and fusion proteins, biologicals with increased complexities and resulting expanded therapeutic effects have been in development over the past years. This session aims to cover the process development and optimization for such multivalent proteins that are challenging to express. Likewise considered are presentations on the production of complex non-antibody proteins and virus-like particles. Difficult-to-express research proteins for small molecule drug development are also within the scope of this session e.g. the generation of purified transmembrane proteins like GPCRs and ion-channels for biophysical methods and structure determination.
♣ Manipulation, Monitoring and Control of Protein Quality
Co-Chairs Georg Schmid, Formerly at F. Hoffmann-La Roche, Switzerland - Reingard Grabherr, University of Natural Resources and Life Sciences, Austria
Recombinant proteins produced from animal cell culture are characterized by their high degree of complexity and the selected expression system as well as process conditions have a significant impact on protein quality. For this session we invite presentations that cover novel approaches and achievements for the manipulation and control of protein quality attributes as pertaining to biologicals as well as research proteins. Topics will encompass but are not limited to host cell line engineering and optimization of process parameters for the control of post-translational modifications e.g. glycan structures and function, prediction of product heterogeneity from scale-down experiments, incorporation of non-natural and labelled amino acids for ADCs or biophysical methods and quality control of protein complexes or virus-like particles. Presentations that address quality issues with bispecific antibodies or other multi-functional proteins are particularly encouraged.
♣ Innovation via Prediction
Co-Chairs Helen Faustrup Kildegaard, Technical University of Denmark – Jonathon Soquet, Merck, Switzerland
Using the power of emerging analytical technologies to study cellular systems, we are generating enormous amounts of data, from cell populations and, more recently, from single cell level. The cost of data generation is still high and appropriate data handling and interpretation is challenging. The data platforms that are being built offer the alluring potential to provide innovative step-changes for production of recombinant proteins, rationalizing protein design and process development.. In this session we encourage presentations that (a) deal with the practicalities of data generation and (b) illustrate how the generated data may be used to predict better approaches to maximize protein expression (amount and quality).
♣ Vaccines and vaccine production
Co-Chairs Kenneth Lundstrom, Pan Therapeuitics, Switzerland - Laura A. Palomares, Universidad National Autonoma de Mexico, Mexico
One of the most relevant applications of recombinant protein production by animal cells is the development of new vaccines. Vaccine development strategies have shifted from the classic utilization of live and attenuated viruses to subunit vaccines targeting surface antigens. Recombinant vaccines are preventing cancer and infectious disease. The use of recombinant technology allows the effective and fast response to emerging infectious diseases. Personalized immunotherapy, especially relevant for cancer immunotherapy, requires the fast expression of recombinant proteins. Tumor-associated antigens, cytokines and antibodies have been engineered for immunization studies. The session aims at discussing the latest development in vaccine research including new vaccine development, systemic administration of purified antigens and cytokines, but also viral and non-viral delivery of nucleic acid-based vaccines in the area of infectious diseases and cancer. Abstracts describing recombinant protein production strategies specifically aimed to improve recombinant vaccine availability and to reduce time to market are also welcome.
♣ Poster Presentations
♣ Industrial Workshops